Nov 02, 2023 4:01 pm EDT MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
Oct 26, 2023 7:30 am EDT MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
Oct 24, 2023 7:30 am EDT MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
Oct 03, 2023 7:30 am EDT MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
Sep 14, 2023 7:30 am EDT MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
Sep 12, 2023 7:30 am EDT MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
Aug 03, 2023 4:01 pm EDT MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
Aug 03, 2023 7:30 am EDT MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120